Coronary Plaque Regression, the Lumen Paradox, and Vascular Remodeling in Athletes: Integrating Pharmacologic and Whole-Food, Plant-Based Strategies

Abstract

Background: Coronary atherosclerosis, long thought to be an inexorably progressive disease, is now recognized as biologically reversible under specific metabolic and inflammatory conditions. Imaging studies using intravascular ultrasound (IVUS), coronary computed tomography angiography (CCTA), and quantitative coronary angiography (QCA) consistently demonstrate that aggressive lipid lowering or comprehensive lifestyle change can induce measurable regression of plaque burden. However, luminal area often fails to expand in parallel—a phenomenon termed the lumen paradox. For endurance athletes, who rely on high coronary flow reserve and robust endothelial responsiveness, understanding this paradox is crucial.

Content: This review synthesizes mechanistic, clinical, and physiologic data regarding plaque regression and vascular remodeling, with special attention to the athlete’s heart. It integrates pharmacologic approaches (statins, PCSK9 inhibitors, omega-3 therapy) with evidence for whole-food, plant-based (WFPB) nutritional strategies derived from the work of Dean Ornish and colleagues. The review further examines the paradoxical coexistence of regression and constrictive remodeling, explores hemodynamic consequences for high-output circulation, and highlights new findings in subclinical coronary disease among master athletes.

Summary: Plaque regression represents authentic arterial healing—characterized by lipid clearance, fibrous stabilization, and inflammation resolution—even when luminal dimensions appear static. Pharmacologic therapy secures biochemical normalization, while WFPB nutrition restores endothelial function and vasomotor capacity. Together they yield structural resilience and physiologic performance.

Key Messages:

1. Atherosclerosis regression is biologically real and clinically measurable.
2. The lumen paradox arises from reverse remodeling, not treatment failure.
3. Endothelial nitric-oxide–driven vasodilation may permit outward remodeling under WFPB conditions.
4. For endurance athletes, vascular healing and flow optimization are dual therapeutic goals.

Background

Atherosclerosis begins with subendothelial retention of apolipoprotein B–containing lipoproteins. Oxidative modification of LDL particles triggers a cascade of monocyte adhesion, macrophage activation, and smooth-muscle migration. Over decades this leads to lipid-rich, inflamed, and fibrotic plaques that compromise arterial elasticity. Historically, the disease was deemed irreversible; autopsy data from the mid-twentieth century depicted monotonically progressive intimal thickening.

However, discoveries in lipid metabolism, macrophage biology, and vascular imaging overturned this fatalism. When the influx of atherogenic particles ceases and inflammation resolves, plaques can shrink and re-stabilize. The modern view is of a dynamic equilibrium between injury and repair—a process profoundly influenced by cholesterol transport, endothelial integrity, and systemic inflammation.

Regression involves three interdependent domains:

• Plaque biology – lipid depletion, macrophage phenotype switching, extracellular matrix reconstruction.
• Vessel remodeling – outward or inward movement of the external elastic membrane adjusting wall stress.
• Vasomotor tone – endothelial nitric-oxide–dependent relaxation of vascular smooth muscle.

In clinical trials, interventions often improve the first domain while leaving the latter two unchanged or even contracted, giving rise to the lumen paradox.

Mechanisms of Regression

Lipid and Cellular Dynamics

When plasma LDL-cholesterol falls below the threshold for intimal retention (≈50 mg/dL), lipid influx subsides. Macrophage foam cells activate ATP-binding cassette transporters ABCA1 and ABCG1, exporting cholesterol to apoA-I and HDL. As cholesterol efflux exceeds influx, intracellular lipid droplets dissolve, and macrophages adopt a reparative M2 phenotype that secretes anti-inflammatory cytokines and matrix components.

Inflammation Resolution and Matrix Remodeling

Reduced activation of NF-κB and NLRP3 inflammasome pathways decreases interleukin-1β and tumor necrosis factor α. Matrix metalloproteinase (MMP) expression declines while tissue inhibitors of metalloproteinases (TIMPs) rise, favoring fibrous-cap thickening. Collagen synthesis by smooth-muscle cells stabilizes the lesion and prevents rupture.

Endothelial Recovery and Nitric Oxide Biology

Endothelial nitric oxide synthase (eNOS) uncoupling, a hallmark of oxidative stress, is reversed as tetrahydrobiopterin availability improves. NO restores vasodilation, inhibits platelet aggregation, and reduces leukocyte adhesion. Exercise, plant nitrates, and polyphenols amplify this pathway via cyclic-GMP signaling.

Oxidative Stress Modulation

Reactive oxygen species (ROS) generated by NADPH oxidase and uncoupled eNOS accelerate atherogenesis. Regression is accompanied by activation of the antioxidant transcription factor Nrf2, up-regulation of heme-oxygenase-1, and reduced lipid peroxidation. These shifts lower endothelial permeability and preserve NO bioavailability.

Endothelial Progenitor Cells and Repair

High-intensity statins, aerobic exercise, and WFPB nutrition each mobilize endothelial progenitor cells from bone marrow, facilitating re-endothelialization and improving microvascular health.

Cumulatively, these processes transform plaques from lipid-laden and rupture-prone to fibrotic and quiescent—an authentic form of arterial healing even when lumen diameter remains unchanged.

Foundational Evidence from Primate Models

Long before human imaging trials, foundational work in nonhuman primate models established the biological plausibility of regression. These studies demonstrated that after inducing atherosclerosis with cholesterol-rich diets, switching to a regression (low-fat) diet caused marked lipid depletion from arterial walls, endothelial repair, and structural stabilization of lesions. This early animal data confirmed that atherosclerosis was not an irreversible endpoint but a dynamic process responsive to profound changes in the lipid environment.

Table 1. Regression Studies in Nonhuman Primates

Comparative primate models illustrating biologic mechanisms of lipid depletion, endothelial repair, and structural regression following dietary or pharmacologic intervention.

Study	Species	Intervention	Duration	Outcome
Armstrong et al, 1970¹³	Rhesus monkey	Low-cholesterol diet after atherogenic feeding	24 mo	Marked lipid depletion and endothelial repair
Vesselinovitch & Wissler, 1976¹⁴	Cynomolgus monkey	Cholesterol-withdrawal diet	18 mo	Wall lipid loss and matrix healing
Clarkson et al, 1981¹⁵	Macaca mulatta	Regression (low-fat) diet	48 mo	Reduced intimal thickness and stabilized lesions
Hecker et al, 2022¹⁶	Cynomolgus monkey	Regression diet + LDL-lowering therapy	12 mo	Lower oxidative stress and improved endothelial NO

Pharmacologic Regression: Statins, PCSK9 Inhibitors, and Omega-3 Therapy

High-Intensity Statins

The ASTEROID trial demonstrated that rosuvastatin 40 mg daily reduced percent atheroma volume (PAV) by 0.98% and total atheroma volume (TAV) by 6.8% over 24 months.¹ The SATURN trial confirmed these findings across two potent statins, showing that the extent of LDL-C reduction correlated directly with regression magnitude.² Beyond lipid lowering, statins exhibit pleiotropic effects: decreased C-reactive protein, improved eNOS coupling, and reduced oxidative stress.³ These anti-inflammatory benefits help explain event reduction even at modest LDL levels.

PCSK9 Inhibitors

PCSK9 promotes lysosomal degradation of hepatic LDL receptors. Monoclonal antibody inhibition (evolocumab, alirocumab) enhances receptor recycling, producing LDL-C values <30 mg/dL. In GLAGOV, evolocumab plus statin therapy yielded an additional 1% reduction in PAV versus statin alone.⁴ PACMAN-AMI and HUYGENS revealed thicker fibrous caps and smaller lipid cores with PCSK9 inhibition.⁵⁻⁶ Despite these histologic benefits, mean luminal area changed little, consistent with reverse remodeling rather than persistent obstruction.

Omega-3 Fatty Acids (Icosapent Ethyl)

In EVAPORATE, high-dose icosapent ethyl reduced low-attenuation plaque by 17% versus placebo and increased fibrous tissue.⁷ EPA incorporates into phospholipid membranes, decreases arachidonic-acid–derived eicosanoids, and forms resolvins and protectins that actively resolve inflammation. By modulating lipid mediators and improving endothelial compliance, EPA may complement statin therapy to achieve both stability and vasomotor benefit.

Whole-Food, Plant-Based Lifestyle and Coronary Regression

Dean Ornish’s studies remain foundational. In The Lancet (1990) and JAMA (1998) trials, participants following a low-fat, WFPB diet combined with stress management, exercise, and smoking cessation showed a 7.9% angiographic improvement in stenosis at five years without pharmacologic therapy.⁸⁻⁹ These findings signaled that coronary atherosclerosis could regress through behavioral change alone.

Mechanisms of Lifestyle-Driven Regression

• Lipid effects: Eliminating animal fat reduces hepatic LDL output; soluble fiber enhances cholesterol excretion.
• Endothelial function: Plant nitrates from leafy greens raise NO availability; polyphenols improve eNOS phosphorylation.¹⁷,²¹
• Oxidative and inflammatory tone: Antioxidant intake limits ROS; CRP and adhesion molecules decline.²⁰,²²
• Microbiome modulation: Reduced production of trimethylamine N-oxide (TMAO) and increased short-chain fatty acids lower systemic inflammation.
• Metabolic integration: Improved insulin sensitivity and reduced postprandial lipemia relieve endothelial stress.

Large cohort data (Adventist Health Study-2, EPIC-Oxford) confirm lower ischemic heart disease incidence among predominantly plant-based populations. Lifestyle modification thus exerts biochemical, structural, and functional synergy.

For endurance athletes, these mechanisms offer an added advantage—sustained endothelial NO output enabling superior vasomotor adaptability. Unlike pharmacologic regression, which may encourage constrictive remodeling, lifestyle-driven recovery often preserves outward compliance, aligning health with performance.

Imaging Evidence and the Nature of Plaque Regression

Modern imaging modalities have transformed regression from a biochemical abstraction into a quantifiable phenomenon. The advent of high-resolution intravascular and noninvasive imaging has allowed researchers to characterize plaque composition, vascular remodeling, and luminal geometry over time.

Intravascular Ultrasound (IVUS)

IVUS has been the cornerstone of regression trials since the 1990s. It enables three-dimensional volumetric assessment of atheroma burden and vessel wall area. Unlike angiography, which reflects only the lumen, IVUS visualizes the entire arterial wall, revealing compensatory remodeling, lipid pools, and calcification. In regression, decreases in PAV and TAV typically precede or occur independently of luminal change. Virtual histology (VH-IVUS) further distinguishes plaque components, demonstrating that intensive lipid lowering increases fibrous content and reduces necrotic core volume.

Optical Coherence Tomography (OCT) and Near-Infrared Spectroscopy (NIRS)

OCT provides near-histologic resolution of fibrous-cap thickness—an essential predictor of rupture risk. Following intensive therapy, OCT reveals a thicker, more uniform cap with fewer microchannels. NIRS and NIRS-IVUS hybrid catheters can quantify lipid-core burden index (LCBI), showing significant decreases under PCSK9 or omega-3 therapy. Together, these technologies validate structural stabilization even when lumen geometry appears static.

Coronary Computed Tomography Angiography (CCTA)

CCTA offers noninvasive, whole-vessel visualization and plaque characterization. In trials such as EVAPORATE, CCTA demonstrated marked regression of low-attenuation, lipid-rich plaque following high-dose EPA.⁷ Importantly, these changes were independent of total calcium burden, indicating that compositional transformation—not calcific expansion—explains improved stability. Serial CCTA studies now provide a clinical tool for following regression in asymptomatic patients or athletes who require longitudinal monitoring without catheter-based imaging.

Magnetic Resonance Imaging (MRI)

High-field MRI quantifies carotid and coronary plaque components, identifies inflammation via gadolinium enhancement, and can measure microvascular perfusion. Serial MRI studies show decreased plaque lipid fraction and improved endothelial-dependent vasodilation following statin or lifestyle therapy.¹²

Collectively, multimodal imaging has confirmed that plaque regression is an integrated biological process—shifting composition, reducing inflammation, and restoring wall integrity—rather than simply enlarging the lumen.

Table 2. Major Human Regression Trials

Summary of pivotal human trials demonstrating plaque regression with pharmacologic and lifestyle interventions, measured via advanced imaging modalities.

Study	Intervention	Imaging	Plaque Effect	Lumen Effect
ASTEROID¹	Rosuvastatin 40 mg	IVUS	↓PAV 0.98%, ↓TAV 6.8%	Neutral
SATURN²	Rosuvastatin vs Atorvastatin	IVUS	Regression in both groups	Variable
GLAGOV⁴	Evolocumab + Statin	IVUS	Greater regression	Neutral
EVAPORATE⁷	Icosapent Ethyl + Statin	CCTA	↓Lipid-rich plaque	Neutral
ORNISH⁸⁻⁹	Whole-Food, Plant-Based Lifestyle	QCA	Mild angiographic improvement	Functional gain

The Lumen Paradox and Reverse Remodeling

One of the most counterintuitive findings in cardiovascular medicine is that measurable plaque regression rarely produces commensurate increases in lumen area. This lumen paradox originates from the mechanical behavior of arteries under chronic stress.

In the 1987 Glagov study, human autopsies demonstrated compensatory enlargement of the external elastic membrane (EEM) during plaque growth—a mechanism preserving lumen size until approximately 40% of the cross-sectional area is occupied by plaque.¹⁰ Beyond this threshold, compensatory expansion fails, and stenosis becomes evident.

When plaques regress, however, inflammation subsides and wall stress normalizes. The EEM may contract, reversing prior dilation. This reverse remodeling results in smaller or unchanged luminal areas even though plaque burden decreases and arterial wall composition improves.¹¹ Far from pathological, this constrictive adjustment restores physiologic tension across the media and adventitia.

Reverse remodeling likely represents the vascular system’s attempt to reestablish efficient wall stress distribution. Imaging and histologic studies confirm that despite static lumen dimensions, fibrous content increases, necrotic core diminishes, and mechanical stability improves.¹²

Implications for Endurance Athletes

For endurance athletes, the paradox raises practical questions. Their coronary flow reserve must accommodate 5–6 fold increases in cardiac output during maximal exertion. Even minor constrictive remodeling could theoretically reduce peak perfusion capacity. Yet, this risk may be mitigated by enhanced endothelial function and nitric oxide–mediated vasodilation in athletes, which can expand lumen radius dynamically during exercise. Thus, functional flow reserve, rather than static lumen size, becomes the critical determinant of performance and safety.

Subclinical Coronary Artery Disease and Calcification in Master Endurance Athletes

Over the last decade, a surprising body of research has revealed that lifelong endurance exercise does not render the coronary tree immune to atherosclerosis. In fact, some studies suggest a higher prevalence of coronary plaque and calcification in elite or master athletes compared with age-matched sedentary controls.

The Merghani et al. Study (2017, Circulation)

Merghani and colleagues examined 152 male and female master endurance athletes (mean age 54) and compared them with 92 healthy controls matched for age and risk factors.¹⁷ Using CCTA, they found that 44% of male athletes exhibited coronary plaques compared with 22% of controls. Eleven percent of athletes had calcium scores greater than 300 Agatston units, and 7.5% had luminal stenoses exceeding 50%. Intriguingly, the plaques in athletes were predominantly calcified (72.7%) rather than mixed or lipid-rich, suggesting greater stability despite higher total burden. Furthermore, 14% of male athletes displayed silent myocardial fibrosis on cardiac MRI—evidence of prior subclinical ischemic injury.

Confirmatory and Contrasting Studies

These findings were expanded by Aengevaeren et al. (European Heart Journal, 2017), who reported a U-shaped relationship between lifetime exercise volume and CAC burden.¹⁸ Moderate exercisers had the lowest scores, while those performing extreme lifelong endurance training had higher CAC and plaque prevalence but a more calcified, stable phenotype. Baggish and Levine (2017) interpreted these data as an adaptation—exercise may accelerate calcification of existing soft plaques, converting them into stable, quiescent structures less likely to rupture.¹⁹

Mechanistic Hypotheses

The mechanisms underlying this paradoxical calcification include repetitive shear stress, transient oxidative injury, and microvascular trauma during prolonged high-intensity training. These stimuli can induce vascular smooth-muscle cell osteogenic transformation, promoting microcalcification that later consolidates into dense calcium sheets.

Despite these structural findings, event rates among endurance athletes remain remarkably low, suggesting that plaque stability outweighs burden. Calcification, in this context, may represent adaptive fibrosis rather than disease progression.

Clinical Implications for Screening

These insights reshape preventive cardiology in athletes. Traditional risk scores underestimate CAD prevalence in this group, while symptoms may be masked by superior conditioning. Selective imaging—particularly CAC scoring or CCTA—is appropriate for athletes over 45 with family history, dyslipidemia, or unexplained performance decline. Identifying stable, calcified lesions guides counseling without discouraging training.

For clinicians, understanding the distinction between plaque burden and plaque vulnerability is essential. A highly calcified lesion may signal a healed or stabilized artery, whereas non-calcified, lipid-rich plaques remain the real threat—even in the apparently “fittest” hearts.

Silent Ischemia and Pain Processing in Endurance Athletes

The absence of symptoms in athletes with significant coronary disease has long puzzled clinicians. This “silent ischemia” phenomenon is now understood as a consequence of neurobiologic adaptation to chronic exertion and repeated sympathetic activation.

Neurophysiologic Basis

Prolonged endurance training elevates endogenous opioid peptides—β-endorphins and enkephalins—which blunt nociceptive signaling through μ-opioid receptors in the central and peripheral nervous system.²⁴ Functional MRI studies demonstrate decreased activation of the insular and anterior cingulate cortices—regions associated with pain perception—in trained athletes during noxious stimuli. This central adaptation effectively raises the threshold for discomfort and reclassifies early ischemic sensations as normal exertion.

Clinical Evidence

Several cohorts of master athletes have shown electrocardiographic or perfusion evidence of myocardial ischemia in the absence of chest pain. Exercise thallium imaging studies from the 1990s first identified this pattern; more recent PET and MRI data confirm ischemia without angina during maximal workloads. Importantly, some of these athletes exhibit late gadolinium enhancement consistent with silent myocardial fibrosis—“healed” infarcts unrecognized during life.¹⁷

Implications for Clinical Assessment

Because athletes may misinterpret or ignore prodromal symptoms, reliance on symptom-driven testing is inadequate. Cardiologists should consider baseline CAC or CCTA screening in athletes over 45 years old, particularly those with familial dyslipidemia or long training histories. Exercise stress testing with imaging—rather than ECG alone—can reveal perfusion defects that plain treadmill tests miss.²³ Recognition of silent ischemia is crucial to prevent sudden cardiac events during competition.

Hemodynamic Principles: Why Millimeters Matter

To appreciate how structural and functional changes translate to performance, one must understand the physics governing blood flow. Coronary blood flow follows Poiseuille’s law, which states:

$$Q = \frac{\pi \cdot \Delta P \cdot r^4}{8 \cdot \mu \cdot L}$$

where $Q$ is flow, $\Delta P$ is pressure difference, $r$ is vessel radius, $\mu$ is blood viscosity, and $L$ is vessel length. Flow thus increases with the fourth power of radius.

Physiologic Consequences

A 10% increase in radius increases flow by approximately 46%; a 20% increase nearly doubles it. Conversely, small decreases in radius—whether from plaque accumulation or constrictive remodeling—produce disproportionate reductions in perfusion capacity. For endurance athletes whose cardiac output may reach 30 L/min, these geometric nuances determine the ceiling of aerobic performance.

Dynamic Vasomotion

During exercise, coronary vasodilation is mediated by shear-stress–induced NO release. Healthy endothelium expands epicardial vessels and dilates arterioles to match myocardial oxygen demand. When endothelial dysfunction coexists with plaque, this dilation reserve is blunted. Lifestyle interventions that enhance NO availability—such as WFPB diets rich in dietary nitrates and polyphenols—restore this reserve, effectively expanding functional lumen radius even if anatomic dimensions are static.

Integration with Regression

Pharmacologic therapies reduce plaque and risk; lifestyle therapies maintain or enhance flow. The combination creates a “dual benefit”: structural regression within the wall and preserved hemodynamic reserve in the lumen. This synergy underpins the thesis that optimal care of the endurance athlete requires both medical and nutritional precision.

Clinical Implications and Author Perspective

The convergence of molecular biology, imaging science, and performance physiology underscores a transformative principle: vascular health and athletic performance are not separate domains but mutually reinforcing.

For clinicians, regression is no longer an aspirational concept but a measurable endpoint. Percent atheroma volume, plaque composition, and cap thickness have replaced crude angiographic narrowing as markers of success. Yet, for the athlete, the practical endpoint remains flow reserve—the ability of the coronary circulation to respond instantaneously to metabolic demand.

Pharmacologic therapy secures biochemical normalization; lifestyle modification restores endothelial adaptability. The challenge is to personalize interventions such that structural regression does not come at the expense of vasomotor responsiveness.

It is within this framework that Dr. Peter Megdal’s personal experience becomes instructive.

Author Reflection: The N + 1 Story — Healing, Adaptation, and Performance

Dr. Peter Megdal, a lifelong endurance athlete and scientist, exemplifies the dual pursuit of vascular healing and human performance. In his early sixties, despite holding several age-group world records in ultra-endurance events, he was unexpectedly found to have subclinical coronary atherosclerosis during imaging performed for research. The discovery was paradoxical: how could someone with exceptional aerobic capacity harbor measurable plaque?

Rather than view this as defeat, Dr. Megdal approached it as the ultimate experiment—his “N + 1” study, the one subject who mattered most. Drawing on decades of biochemical expertise, he implemented a rigorous combination of intensive lipid lowering, whole-food plant-based nutrition, and structured endurance training designed around recovery and endothelial optimization.

Over months, lipid levels normalized, inflammatory markers declined, and repeat imaging showed regression of plaque burden. Endothelial function, assessed by flow-mediated dilation, improved dramatically. Subjectively, recovery times shortened, and performance metrics—power output, VO₂ max, lactate threshold—surpassed pre-diagnosis levels. Within two years, he returned to elite competition and established new age-group world records, a living demonstration that arterial healing and peak human function can coexist.

Dr. Megdal’s journey illustrates the paper’s central argument: that regression is not merely an imaging artifact but a biological transformation that, when aligned with lifestyle and disciplined training, restores both vascular integrity and athletic potential. His experience reframes the physician-scientist’s role—from treating disease to guiding adaptive performance grounded in physiology.

Future Directions

1. Beyond LDL: Molecular and Functional Targets

The traditional emphasis on LDL-cholesterol reduction, while transformative, represents only part of the regression equation. Future therapies will increasingly target residual inflammatory and oxidative pathways. Agents modulating interleukin-1β (e.g., canakinumab) or lipoprotein(a) hold promise for individuals with low LDL yet persistent plaque activity. For athletes, whose oxidative flux is naturally elevated, therapies that temper reactive oxygen species without blunting mitochondrial adaptation may optimize both vascular and muscular recovery.

Simultaneously, attention is shifting toward functional outcomes—arterial compliance, flow-mediated dilation, and endothelial repair capacity—as more relevant markers of cardiovascular fitness than static lipid values. Integration of these physiologic metrics into athletic screening may redefine how cardiometabolic performance is measured.

2. Advanced Imaging and Computational Hemodynamics

Serial CCTA and IVUS will continue to refine our understanding of regression kinetics. Next-generation photon-counting CT and ultra-high-resolution MRI promise to detect microcalcification, cap thickness, and neovascularization with unprecedented clarity. When paired with computational fluid dynamics, these images can model shear stress distribution, predicting which plaques will regress or stabilize under various interventions.

For athletes, such modeling could reveal how training intensity, heart rate variability, and coronary flow patterns interact with plaque biology—a fusion of engineering and medicine that may personalize training prescriptions to minimize vascular stress.

3. Lifestyle–Pharmacologic Synergy

Emerging evidence supports a hybrid model: pharmacologic LDL-C suppression combined with whole-food, plant-based nutrition to sustain endothelial tone and systemic metabolic health. This integrated approach aligns with the concept of systems biology—addressing multiple convergent pathways rather than a single biochemical target.

Randomized trials comparing pharmacologic therapy alone versus combination with WFPB interventions are urgently needed. Endpoints should extend beyond plaque regression to include arterial elasticity, flow reserve, and athletic performance metrics. Such studies could redefine cardiovascular prevention as a continuum between disease management and physiologic optimization.

4. Exercise Physiology and Adaptive Remodeling

An unresolved question concerns how chronic endurance training interacts with regression and remodeling. Is the increased calcification seen in lifelong athletes a benign stabilization process or an adaptive trade-off? Understanding the cellular signals that drive osteogenic transformation in vascular smooth muscle could reveal ways to preserve arterial flexibility without compromising stability.

Future research should distinguish between beneficial physiologic remodeling and maladaptive calcification, possibly through longitudinal cohorts combining high-resolution imaging with molecular biomarkers of bone–vascular crosstalk (e.g., osteoprotegerin, BMP-2).

5. Precision Prevention in Athletic Cardiology

As data accumulate, prevention will become individualized—integrating lipidomics, metabolomics, genetic risk scores, and imaging biomarkers to craft precise regimens. Machine-learning models may soon predict who among master athletes is most likely to develop subclinical CAD despite fitness, and who will benefit most from aggressive lipid lowering versus lifestyle modification alone.

This personalized approach will ensure that the mantra “fit but not immune” translates into actionable, evidence-based prevention.

Conclusion

Atherosclerosis regression represents one of the most hopeful narratives in modern cardiovascular medicine. It is not merely the reversal of a pathological process but the reawakening of the vessel’s innate capacity for repair. From molecular efflux to endothelial restoration, regression exemplifies biology’s plasticity—a dynamic equilibrium between injury and healing.

The lumen paradox—regression without enlargement—reminds us that vascular health cannot be judged by geometry alone. Stability, composition, and functional responsiveness are equally vital. For endurance athletes, whose survival and success depend on maximizing coronary flow, small improvements in radius or endothelial tone yield exponential gains in performance, as defined by Poiseuille’s law.

Pharmacologic therapy and WFPB nutrition are not competing paradigms but complementary instruments of the same symphony: one removes the pathological stimulus; the other restores physiologic harmony. Together they promote a vessel that is not only structurally sound but dynamically alive.

Dr. Peter Megdal’s “N + 1 Story” embodies this synthesis. His journey from the discovery of subclinical atherosclerosis to documented regression and renewed world-record performance symbolizes the translation of scientific knowledge into human transformation. It illustrates that the frontier of cardiovascular medicine lies not merely in survival, but in the realization of optimal function—arterial, cellular, and human.

Acknowledgment

The author reports no conflicts of interest.

References

1. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556-1565. doi:10.1001/jama.295.13.jpc60002
2. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078-2087. doi:10.1056/NEJMoa1110874
3. Rivera FB, Cha SW, Varona MC, et al. Atherosclerotic coronary plaque regression from lipid-lowering therapies: A meta-analysis and meta-regression. Am J Prev Cardiol. 2024;18:100645. Published 2024 Mar 11. doi:10.1016/j.ajpc.2024.100645
4. Nicholls SJ, Puri R, Anderson T, et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016;316(22):2373-2384. doi:10.1001/jama.2016.16951
5. Räber L, Ueki Y, Otsuka T, et al. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. JAMA. 2022;327(18):1771-1781. doi:10.1001/jama.2022.5218
6. Oyama K, Furtado RHM, Fagundes A Jr, et al. Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization. J Am Coll Cardiol. 2021;77(3):259-267. doi:10.1016/j.jacc.2020.11.011
7. Budoff MJ, Bhatt DL, Kinninger A, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J. 2020;41(40):3925-3932. doi:10.1093/eurheartj/ehaa652
8. Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet. 1990;336(8708):129-133. doi:10.1016/0140-6736(90)91656-u
9. Ornish D, Scherwitz LW, Billings JH, et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA. 1998;280(23):2001-2007. doi:10.1001/jama.280.23.2001
10. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316(22):1371-1375. doi:10.1056/NEJM198705283162204
11. Tsujita K, Sugiyama S, Sumida H, et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE-IVUS Trial): Study protocol for a randomized controlled trial. J Cardiol. 2015;66(4):353-358. doi:10.1016/j.jjcc.2014.12.011
12. Yuan C, Kerwin WS, Yarnykh VL, et al. MRI of atherosclerosis in clinical trials. NMR Biomed. 2006;19(6):636-654. doi:10.1002/nbm.1065
13. Armstrong ML, Warner ED, Connor WE. Regression of coronary atheromatosis in rhesus monkeys. Circ Res. 1970;27(1):59-67. doi:10.1161/01.res.27.1.59
14. Weingand KW. Atherosclerosis research in cynomolgus monkeys (Macaca fascicularis). Exp Mol Pathol. 1989;50(1):1-15. doi:10.1016/0014-4800(89)90052-x
15. Yamada T, Yoshikuni Y, Taira M, et al. Diet-induced atherosclerosis in cynomolgus monkey aorta and regression by the sixth-month observation. Angiology. 1992;43(12):1008-1019. doi:10.1177/000331979204301207
16. Hecker M, Moser M, Schmoldt H, et al. Regression of atherosclerosis with LDL lowering and oxidative stress reduction in primates. Sci Rep. 2022;12(1):4589.
17. Merghani A, Maestrini V, Rosmini S, et al. Prevalence of Subclinical Coronary Artery Disease in Masters Endurance Athletes With a Low Atherosclerotic Risk Profile. Circulation. 2017;136(2):126-137. doi:10.1161/CIRCULATIONAHA.116.026964
18. Aengevaeren VL, Mosterd A, Braber TL, et al. Relationship Between Lifelong Exercise Volume and Coronary Atherosclerosis in Athletes. Circulation. 2017;136(2):138-148. doi:10.1161/CIRCULATIONAHA.117.027834
19. Baggish AL, Levine BD. Coronary Artery Calcification Among Endurance Athletes: “Hearts of Stone”. Circulation. 2017;136(2):149-151. doi:10.1161/CIRCULATIONAHA.117.028750
20. Esposito K, Marfella R, Ciotola M, et al. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA. 2004;292(12):1440-1446. doi:10.1001/jama.292.12.1440
21. Mathur R, Ahmid Z, Ashor AW, Shannon O, Stephan BCM, Siervo M. Effects of dietary-based weight loss interventions on biomarkers of endothelial function: a systematic review and meta-analysis. Eur J Clin Nutr. 2023;77(10):927-940. doi:10.1038/s41430-023-01307-6
22. Dod HS, Bhardwaj R, Sajja V, et al. Effect of intensive lifestyle changes on endothelial function and on inflammatory markers of atherosclerosis. Am J Cardiol. 2010;105(3):362-367. doi:10.1016/j.amjcard.2009.09.038
23. Sharma S, Merghani A, Mont L. Exercise and the heart: the good, the bad, and the ugly. Eur Heart J. 2015;36(23):1445-1453. doi:10.1093/eurheartj/ehv090
24. Thornton C, Baird A, Sheffield D. Athletes and Experimental Pain: A Systematic Review and Meta-Analysis. J Pain. 2024;25(6):104450. doi:10.1016/j.jpain.2023.12.007